CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma

Figure 1 Flowchart of the CRAFITY score. AFP: Alpha-fetoprotein; CRP: C-reactive protein.

Figure 2 Kaplan-Meier curves of progression-free survival and overall survival across different CRAFITY groups. A: Kaplan-Meier curves of progression-free survival; B: Kaplan-Meier curves of overall survival. PFS: Progression-free survival; OS: Overall survival.

Figure 3 Kaplan-Meier curves of progression-free survival and overall survival in patients with or without cirrhosis. A: Kaplan-Meier curves of progression-free survival; B: Kaplan-Meier curves of overall survival. PFS: Progression-free survival; OS: Overall survival.

Figure 4 Forest plot of multivariate Cox regression for progression-free survival and overall survival. A: Forest plot for progression-free survival; B: Forest plot for overall survival. PVTT: Portal vein tumor thrombus; TACE: Transarterial chemoembolization; EHM: Extrahepatic metastasis.

Figure 5 Predictive model. A: Nomogram for predicting overall survival at 1-year; B: Receiver operating curve of the nomogram; C: Calibration curve of the nomogram. TACE: Transarterial chemoembolization; AUC: Area under the curve; OS: Overall survival.